Outpatient Facility Coding Alert - 2003 Issue 24
Pharmaceuticals: WYDEN: NIH IGNORED PATIENT, TAXPAYER COSTS FOR TAXOL
Subscribe or sign in to view the full article.
Article Overview
This piece covers a General Accounting Office analysis released by Sen. Ron Wyden on NIH’s handling of rights related to Taxol, a cancer drug developed with substantial federal research involvement. It explains why the article matters for readers tracking pharmaceutical policy, federal technology transfer, Medicare purchasing concerns, and the impact of patent strategy on access and taxpayer value. The article also places the NIH-Bristol-Myers Squibb collaboration in the context of clinical development, pricing expectations, royalty returns, and later legal challenges connected to market exclusivity.
Why This Topic Matters
The article is relevant to readers interested in how federal agencies negotiate pharmaceutical partnerships, how public research investments are monetized, and how pricing and exclusivity decisions can affect patients and government purchasers. It is especially useful for policy, reimbursement, and pharmaceutical industry audiences following drug-development collaborations and antitrust disputes.
Article Sections
-
GAO analysis of the NIH-Taxol agreement
Summarizes the government review of the collaboration and the concerns raised about the public return from the agreement. It frames the policy and taxpayer issues discussed in the article.
-
Federal investment, royalties, and pricing concerns
Describes the public funding behind the drug’s development and the financial outcomes reported by the government analysis. It also covers the article’s discussion of pricing expectations for federally connected purchasers.
-
NIH response and development context
Presents NIH’s explanation of the collaboration’s benefits and the role of the partnership in supporting clinical development. It contrasts the agency’s view with the earlier criticism.
-
Patent strategy and market exclusivity disputes
Discusses later patent-related developments and legal challenges tied to the drug’s market position. It includes the broader competitive and exclusivity context described in the article.
What You Will Learn
- How a federal review evaluated a public-private pharmaceutical collaboration
- What broad issues can arise when public research supports a commercial drug
- Why pricing and purchasing concerns matter for federal healthcare programs
- How patent strategy can affect a drug’s market exclusivity over time
- How government, industry, and legal responses can differ after a drug reaches market
Who Should Read This
- Medical coders and billing professionals following pharmaceutical policy
- Healthcare compliance and reimbursement staff
- Pharmaceutical policy analysts
- Health law and antitrust readers
- Payers and public program stakeholders
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com